FDA Acknowledges More Diverse Subgroup Data Needed In Trials
Executive Summary
FDASIA-mandated report indicates some trials underrepresented some racial groups, but the agency says those subsets may not be the proper groupings in the era of personalized medicine.
You may also be interested in...
US FDA Extends Race/Ethnicity Clinical Data Collection Guidelines To Observational Studies
However, new draft guidance expressly does not address diversity action plans required under Food and Drug Omnibus Reform Act; initial guidance on these plans was due in December 2023 but has yet to be released.
Clinical Trial Diversity: FDA Rejects Calls For Enrollment Mandates
Requiring that underrepresented populations be enrolled based upon disease prevalence is only way to ensure adequate diversity, some stakeholders say; agency continues to prefer more flexible approach offered by guidance, and PhRMA says mandates would lengthen development timelines for new drugs.
PDUFA Reaches Approval Altitude; Can House Maintain Senate Speed?
After about a week of debate, the Senate overwhelmingly passes its FDA user fee package, with only track and trace to be finalized. House members are scheduled to begin floor debate after Memorial Day in the hopes of sending the bill to President Obama before July 4.